Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.
Dill V, Kauschinger J, Hauch RT, Buschhorn L, Odinius TO, Müller-Thomas C, Mishra R, Kyncl MC, Schmidt B, Prodinger PM, Hempel D, Bellos F, Höllein A, Kern W, Haferlach T, Slotta-Huspenina J, Bassermann F, Peschel C, Götze KS, Waizenegger IC, Höckendorf U, Jost PJ, Jilg S.
Dill V, et al. Among authors: hollein a.
Eur J Haematol. 2020 Feb;104(2):125-137. doi: 10.1111/ejh.13354. Epub 2019 Dec 8.
Eur J Haematol. 2020.
PMID: 31758597
Clinical Trial.